The National Lottery Community Fund
Cancer52 is grateful for a three-year funding stream from The National Lottery Community Fund, the largest community funder in the UK. The funding was secured as a recognition of Cancer52's achievements, in partnership with members, within and for the rare and less common cancer community. All with the shared aim of improving outcomes for patients.
From January 2024, the funding will be used to
-
Policy advances for rare and less common cancer
-
Addressing patient health inequalities
-
Membership engagement
The intended impact of this funding will be beneficial for patients, Cancer52 and its charity members, and the wider rare and less common cancer community.
Cancer52 is very appreciative of National Lottery players for this support.
Autolus logo
Be One pharma company logo.
Kyowa Kirin brand logo, featuring red letters on a white background.
Corporate Supporter Programme
Working with Cancer52 offers a unique opportunity to access the expertise and knowledge gained through the relationships Cancer52 enjoys with its member organisations, which are very close to patients in their field.
Cancer52 brings these organisations together into a single voice for people with rare and less common cancers which is heard at the highest level of cancer policy and influencing.
Cancer52 seeks donations from its members as well as financial support from outside its membership.
Cancer52 is also grateful to receive support from the organisations shown.
All the corporate supporters listed have made a financial contribution but have no influence over Cancer52 practices, resources or materials produced.
If you would like to learn more about joining the Corporate Supporter Programme, please get in touch.
Collaborations
Cancer52 is a member of the following organisations:
Cancer52 works collaboratively with a number of organisations. Recent collaborators include:
Costello Medical logo
GRAIL biotech company logo
Illumina logo.
Iqvia logo